Aberrant p53 staining was seen in 93% of patients with high-grade uterine serous carcinoma, 15% of patients with high-grade endometrioid uterine carcinoma, and 100% of patients with clear cell uterine adenocarcinoma. This evidence concerns the gene TP53 and endometrial endometrioid adenocarcinoma.